Albert Einstein College of Medicine

Gerotherapeutic drugs target ageing pathways to prevent ageing-related diseases and extend lifespan. Key candidates like metformin, rapamycin, and NAD precursors are in clinical trials. Challenges include designing feasible trials to prove efficacy and safety for licensing. Research also explores exceptional longevity populations for novel drug targets.

Calico, Google's health venture aimed at combating aging, remains shrouded in secrecy despite its ambitious mission and significant funding. Researchers express frustration over the lack of transparency and collaboration, questioning the effectiveness of Calico's approach to aging research. The company's secretive culture, possibly influenced by its leadership's ties to Apple, contrasts with the scientific community's push for openness and data sharing.